According to budget projections, filgrastim biosimilars could save health insurers millions of dollars each year as they seize more market share from the branded drug, Neupogen, a granulocyte colony-stimulating factor (G-CSF).
The analysis was presented by Susan Gabriel, director of global health economics and outcomes research for Teva Pharmaceuticals, at the American Society of Hematology’s 2016 meeting. It assessed the potential monetary impact on payers of increased use of filgrastim-sndz, sold by Sandoz as Xarxio, and tbo-filgrastim, sold by Teva as Granix.
Tbo-filgrastim is not technically regarded as a biosimilar, as it preceded the development of the FDA’s biosimilars approval pathway, but its Biologics License Application was approved after it demonstrated comparable safety, efficacy, and pharmacokinetic activity to Neupogen.
Analysts ran a model, which assumed that tbo-filgrastim would take 5% of the market share over a 1-year period and filgrastim-sndz would take 2%, resulting in a total 7% loss of market share for filgrastim. They calculated the annual drug cost per patient based on a regimen of 6 cycles of 10 days each. Their estimates for the yearly per-patient costs in both medical benefits and pharmacy benefits are as follows:
Overall, the use of short-acting G-CSFs for 1 million members would cost a health plan $177.1 million annually under the current scenario and $175.2 million in the future scenario, representing a yearly saving of almost $2 million. The model was sensitive to changes in the proportion of patients whose G-CSF drugs are administered by their healthcare providers, and to fluctuations in the average price per dose of filgrastim.
G-CSFs like filgrastim are used to fight neutropenia in patients receiving chemotherapy, as they work similar to the body’s proteins that signal to the bone marrow to produce more neutrophils. Neutropenia is a common and serious complication for many cancer patients, as it can result in severe infections and even death.
Due to the high price tag of the branded drug, payers, clinicians, and patients alike are looking to biosimilars as a potentially less expensive solution.
“Based on these assumptions, a million-member health plan could save almost $2 million per year by switching over to tbo-filgrastim as opposed to filgrastim or filgrastim-sndz,” Gabriel concluded. “However, as with any budget impact model, estimated results based on future product market share should be interpreted cautiously.”
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.